Skip to main content

Table 1 Baseline demographic and clinical characteristics of the study population

From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage

Variables

Group A

Group B

Group C

P- value

Numbers

16

16

16

-

Age, y

53.1 ± 6.3

46.9 ± 11.7

49.8 ± 10.1

0.288*

Sex, male/female

8/8

9/7

10/6

0.776†

Hypertension (%)

43.75%

50%

31.25%

0.549†

Vitreous hemorrhage grading scale

   

0.557†

2

3

2

2

 

3

4

3

2

 

4

9

11

12

 
  1. * Kruskal–Wallis H test. † χ2 test